Parallax Volatility Advisers
ACHN

Parallax Volatility Advisers’s Achillion Pharmaceuticals ACHN Stock Holding History

Parallax Volatility Advisers’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-1,800
Closed -$8K – 4589
2017
Q1 		$8K Buy
+1,800
New +$7.47K ﹤0.01% 3230
2015
Q1 		– Sell
-175,000
Closed -$2.14M – 5940
2014
Q4 		$2.14M Buy
+175,000
New +$2.14M 0.01% 1050

Other funds holding ACHN

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Parallax Volatility Advisers's ACHN Position: Q1 2018 in Review

Parallax Volatility Advisers sold out of Achillion Pharmaceuticals (ACHN) in Q1 2018, closing a stake of 18,312 shares — an estimated $53K sold.

Parallax Volatility Advisers first reported a position in ACHN in Q3 2014 and held it in 2 quarters. The position peaked at $53K in Q4 2017. 127 funds tracked by Wall St. Rank hold ACHN as of Q1 2018.

  • Parallax Volatility Advisers reported no remaining Achillion Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Parallax Volatility Advisers sold 18,312 Achillion Pharmaceuticals shares in Q1 2018, an estimated $53K.
  • Parallax Volatility Advisers first reported a position in Achillion Pharmaceuticals in Q3 2014 and held it in 2 quarters.
  • Parallax Volatility Advisers's Achillion Pharmaceuticals position peaked at $53K in Q4 2017.
  • 127 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q1 2018.

Based on Parallax Volatility Advisers's 13F filing for Q1 2018, filed 15 May 2018.